UNSPSC 51142311: Nalmefene hydrochloride dihydrate

This classification denotes an opiate antagonist C21H25NO3.ClH.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 52Z0G7QVJX, chemically known as morphinan-3,14-diol, 17-(cyclopropylmethyl)-4,5-epoxy-6-methylene-, hydrochloride, hydrate (1:1:2), (5.alpha.)-, but more generally known as nalmefene hydrochloride dihydrate, which bears US NIH Compound Identifier 46209574. Most nations, for tariff and trade purposes, schedule nalmefene hydrochloride dihydrate under HS 29391900 and SITC 54141.

As of Q4 2014, NALMEFENE HYDROCHLORIDE DIHYDRATE remains US FDA's Preferred Term for this commodity. SMILES: C=C1CC[C@]2([C@H]3CC4CCC(C5C4[C@]2([C@H]1O5)CCN3CC6CC6)O)O.O.O.CL.

UNSPSC 51142311 Nalmefene hydrochloride dihydrate is a Commodity code that captures state and local procurement of opioid antagonist and pharmaceutical products for emergency response, public health, and pharmacy benefit programs. State and local buyers under this code source naloxone, drug deactivation systems, and generic pharmaceuticals through direct purchasing, cooperative agreements, and pharmacy benefit initiatives. Issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The scope reflects community health priorities—emergency overdose response and controlled pharmaceutical distribution—alongside broader state pharmacy benefit modernization efforts seeking direct manufacturer relationships to manage costs and improve supply chain efficiency.

Activity clusters in Florida and Minnesota, with Texas state-level engagement in exploratory procurement for pharmacy benefit restructuring. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, responses due July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. Texas Health and Human Services Commission issued exploratory Request for Information HHS0017013 in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs operating outside traditional pharmacy benefit manager arrangements. All three opportunities emphasize compliance with federal drug supply chain security requirements, E-Verify, workers' compensation and liability insurance, and fixed-fee or competitive pricing structures.